Researchers at the Perelman School of Medicine at the University of Pennsylvania have uncovered a critical biological mechanism that may…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a rapidly emerging biotech firm previously known as Somite AI, has secured global rights to a pioneering clinical-stage…
Read More
A Noninvasive Treatment Offers Relief for Parkinson’s Disease Symptoms
The development of noninvasive treatments for Parkinson’s disease represents a significant stride in managing a neurodegenerative disorder that affects millions…
Read More
Novo Nordisk Hands a Parkinson’s Cell Therapy to Cellular Intelligence, a Startup Trying to Design Cell Behavior
In a significant move poised to reshape the landscape of Parkinson’s disease treatment and the broader cell therapy sector, Cellular…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The Unapproved QUAD Cocktail: A Closer Look at its Composition QUAD is a compounded sublingual dose product marketed by MEDVi…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a burgeoning biotech startup, has announced the acquisition of global rights to a clinical-stage Parkinson’s disease cell therapy,…
Read More
Cellular Intelligence Licenses Novo Nordisk’s Parkinson’s Cell Therapy Program Following Company’s Strategic Pivot
Seven months after Danish pharmaceutical giant Novo Nordisk officially shuttered its dedicated cell therapy unit in October 2025, a significant…
Read More
Tavapadon Poised for Competitive Parkinson’s Disease Market Following Promising Tremor Data
AbbVie’s tavapadon, an investigational oral once-daily dopamine D1/D5 partial agonist, is nearing a potential regulatory submission, bolstered by new post-hoc…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
In the wake of The New York Times’ April 2 profile, which painted MEDVi CEO Matthew Gallagher as a "vibe-coded…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
